[Future therapeutic strategies for multiple myeloma].

Multiple myeloma (MM) is still one of the most difficult hematological diseases. It is distinguished by recurrent relapses despite successful treatment. Proteasome inhibitors, immunomodulatory imide drugs, and monoclonal antibodies have all been developed in the last 10 years as treatment options for MM. However, obtaining a long-term treatment-free period for relapsed and refractory multiple myeloma (RRMM) remains difficult. The most recent and intriguing research is on new BCMA-targeting therapies. CAR-T cell therapy, in particular, has shown promising results in the treatment for triple class refractory MM patients. BCMA CAR-T cell therapy is gaining attention as a potentially game-changing treatment for multiple myeloma. Fortunately, CAR-T cell therapy will be available in Japan in January 2022. However, numerous issues must be addressed. Many RRMM patients receive CAR-T cell therapy, for example, relapse, and progression-free survival are short. This section provides an overview of clinical study results for CAR-T cell therapy targeting BCMA, and the antibody-drug conjugate, bispecific antibodies, selinexor, and venetoclax.